Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor Resources
Investor News
Share Price / Index
August 24, 2026
Not intended for U.S. and UK Media
Bayer’s sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer
August 04, 2026
Second quarter of 2026:
Bayer operationally on track, decisive progress on strategic priorities
July 30, 2026
Not intended for U.S. and UK Media
Bayer submits application for next indication of Kerendia in China
Discover More
